Salix Pharmaceuticals, Ltd. Reports 3Q2011 Results and Raises 2011 Guidance
RALEIGH, N.C.--(BUSINESS WIRE)--Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced financial and operating results for the third quarter ended September 30, 2011 and other business updates.
Total product revenue was $146.2 million for the third quarter of 2011, an 81% increase compared to $80.6 million for the third quarter of 2010. Total product revenue for the first nine months of 2011 was $385.3 million, a 76% increase compared to $218.5 million for the first nine months of 2010. XIFAXAN® revenue for the third quarter of 2011 was $96.7 million, a 48% increase compared to $65.2 million for the third quarter of 2010.
Total product revenue was $146.2 million for the third quarter of 2011, an 81% increase compared to $80.6 million for the third quarter of 2010. Total product revenue for the first nine months of 2011 was $385.3 million, a 76% increase compared to $218.5 million for the first nine months of 2010. XIFAXAN® revenue for the third quarter of 2011 was $96.7 million, a 48% increase compared to $65.2 million for the third quarter of 2010.